leadf
logo-loader
viewMountain Valley MD Holdings Inc
(
CSE:MVMDOTCQX:MVMDF
)

Mountain Valley MD Holdings poised for animal trials on its Ivectosol 1% solution

Husbandry animal trials are set to start with a third-party preclinical contract research organization (CRO)

Mountain Valley MD Holdings Inc -
Ivectosol 1% will be tested using advanced intra-muscular needleless injection to prove superior pharmacokinetics compared to current commercially available products

Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCQB:MVMDF) (FRA:20MP) is to begin animal trials of its injectable Ivectosol 1% solution, potentially opening up valuable new markets for the company's technology such as in game and poultry. 

Husbandry animal trials are set to start with a third-party preclinical contract research organization (CRO), the biotech and life sciences group said in a statement. 

READ: Mountain Valley MD sees its first revenue via deal with Circadian Wellness for Quicksome technology

Ivectosol 1% will be tested using advanced intra-muscular needleless injection to prove superior pharmacokinetics compared to current commercially available products in terms of CMAX (peak serum concentration that a drug achieves) and AUC (area under the curve) with targeted drug withdrawal times within 10 days of administration.

"We believe these pivotal studies in swine cattle and especially poultry will highlight the advantages of Ivectosol 1% over any existing competitive product today," said Mike Farber, director of life sciences at Mountain Valley MD. 

"We anticipate Ivermectin's antiviral qualities to prove extremely valuable to control outbreaks of influenza viruses such as H5N1 and H5N8 in poultry and the ability to use needleless applicators to inject Ivectosol 1% will be game changing for the livestock and poultry industries."

CEO Dennis Hancock added: "This is a very significant project that will move very quickly and will form the basis for our submissions in new animal drug applications to the Food and Drug Administration."

The company has also hired experienced vet Dr Michel Rondeau as an advisor who, the firm said, will be overseeing the study and driving global pharmaceutical husbandry applications as part of the company's ongoing business commercialization.

"I am honoured to be working with Mountain Valley MD in this advisory capacity and driving such transformational work that has the potential to broadly transform the animal health industry globally," he said.

"These studies, which will be overlooked by Dr. Rondeau, are in line with MVMD's belief that treating potential pandemic diseases in their zoonotic hosts can prevent further outbreaks in humans by eliminating their ability for transmission," it added.

Mountain Valley MD Holdings says it is building a world-class biotech and life sciences company centered around the implementation of its patented Quicksome oral drug formulation and delivery technologies.

Contact the author at giles@proactiveinvestors.com

Quick facts: Mountain Valley MD Holdings Inc

Follow
CSE:MVMD

Price: 0.26 CAD

Market Cap: $85.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Mountain Valley MD preparing to start pre-clinical trials for use of...

Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling from Proactive to bring news the company has filed a cancer patent for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad...

on 4/5/21

2 min read